Viewing Study NCT02142335

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:36 PM
Ignite Modification Date: 2026-02-28 @ 2:50 AM
Study NCT ID: NCT02142335
Status: UNKNOWN
Last Update Posted: 2014-05-20
First Post: 2014-03-25
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Sponsor: California Cancer Assocaties for Research & Excellence
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Malignant Melanoma of Skin Stage III View
None Metastatic Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None B-Raf, inoperable stage III melanoma, metastatic stage IV melanoma, View